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Abstract
Introduction: This study was performed to evaluate the attenuation of osteoarthritic (OA) pathogenesis via
disruption of the stromal cell-derived factor-1 (SDF-1)/C-X-C chemokine receptor type 4 (CXCR4) signaling with
AMD3100 in a guinea pig OA model.
Methods: OA chondrocytes and cartilage explants were incubated with SDF-1, siRNA CXCR4, or anti-CXCR4
antibody before treatment with SDF-1. Matrix metalloproteases (MMPs) mRNA and protein levels were measured
with real-time polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA), respectively.
The 35 9-month-old male Hartley guinea pigs (0.88 kg ± 0.21 kg) were divided into three groups: AMD-treated
group (n = 13); OA group (n = 11); and sham group (n = 11). At 3 months after treatment, knee joints, synovial
fluid, and serum were collected for histologic and biochemical analysis. The severity of cartilage damage was
assessed by using the modified Mankin score. The levels of SDF-1, glycosaminoglycans (GAGs), MMP-1, MMP-13,
and interleukin-1 (IL-1b) were quantified with ELISA.
Results: SDF-1 infiltrated cartilage and decreased proteoglycan staining. Increased glycosaminoglycans and MMP-
13 activity were found in the culture media in response to SDF-1 treatment. Disrupting the interaction between
SDF-1 and CXCR4 with siRNA CXCR4 or CXCR4 antibody attenuated the effect of SDF-1. Safranin-O staining
revealed less cartilage damage in the AMD3100-treated animals with the lowest Mankin score compared with the
control animals. The levels of SDF-1, GAG, MMP1, MMP-13, and IL-1b were much lower in the synovial fluid of the
AMD3100 group than in that of control group.
Conclusions: The binding of SDF-1 to CXCR4 induces OA cartilage degeneration. The catabolic processes can be
disrupted by pharmacologic blockade of SDF-1/CXCR4 signaling. Together, these findings raise the possibility that
disruption of the SDF-1/CXCR4 signaling can be used as a therapeutic approach to attenuate cartilage
degeneration.
Introduction
Osteoarthritis (OA) is one of the most common and dis-
abling diseases in the elderly, affecting nearly 80% of
individuals older than 75 years [1]. Current pharmacolo-
gic therapy is largely ineffective at altering progression
of the disease because the mechanisms for OA remain
elusive.
Chondrocytes are the only cells present in cartilage.
They are responsible for the maintenance and repair of
the normal extracellular matrix, and they are central to
the pathophysiologic processes involved in matrix degra-
dation during OA. The precise mechanism by which
chondrocytes induce matrix degradation under osteoar-
thritic conditions is unclear. To this point, research has
focused largely on the inflammatory cytokines, in parti-
cular interleukin-1b (IL-1b) and tumor necrosis factor-a
(TNF-a) [2]. Reducing inflammatory cytokine levels with
corticosteroids effectively alleviates the symptoms of
osteoarthritis, but it does not prevent the progression of
the disease [3-5].
Chemokines, which have been less studied in the con-
text of osteoarthritis, are a family of small, soluble che-
moattractive cytokines that direct movement of nearby
responsive cells. Chemokines have also been shown to
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influence cell morphology, proliferation, differentiation,
and other activities through the transmembrane G-pro-
tein-coupled receptors [6,7]. Of particular interest in carti-
lage biology is stromal cell-derived factor 1 (SDF-1), an 8-
kDa chemokine originally isolated from bone marrow stro-
mal cells [8]. SDF-1 activates a wide variety of primary
cells by binding to the G-protein-coupled receptor,
CXCR4 [7]. The SDF-1/CXCR4 axis is unique in that
SDF-1 is the only known ligand of CXCR4 [9]. In the
joint, SDF-1 is synthesized in the synovium, and CXCR4 is
expressed by articular chondrocytes [10].
SDF-1 and CXCR4 play a critical role in movement of
stem cells out of the bone marrow and into the circulating
bloodstream [8,11,12], and SDF-1/CXCR4-knockout mice
exhibit significant developmental abnormalities that lead
to embryo death [13]. Interestingly, SDF-1 and CXCR4 are
expressed during development in a complementary pat-
tern in a variety of adjacent tissue pairs, which include car-
diac, vascular, hematopoietic, and craniofacial tissues [9].
This complementary expression pattern suggests a para-
crine regulatory mechanism whereby tissues producing
SDF-1 can induce the development of the adjacent tissues
that express CXCR4. A similar expression pattern has also
been found in the growth-plate cartilage [14].
Recent evidence suggests that SDF-1/CXCR4 may play a
role in the progression of OA. First, a dramatic increase of
SDF-1 is found in the synovial fluid from the knee joints
of rheumatoid arthritis and OA patients [10]. Second, in
vitro experiments have demonstrated that SDF-1 regulates
chondrocyte catabolic activity [10,15] by stimulating the
release of MMP-3 and MMP-13 [7,10]. And third, syno-
vectomy significantly reduces the serum concentrations of
SDF-1, MMP-9, and MMP-13 [15]. These findings
strongly suggest that SDF-1 influences cartilage matrix
degeneration by stimulating the release of MMPs from
chondrocytes.
This study was performed to explore further the role
of SDF-1 and CXCR4 in OA pathogenesis by manipulat-
ing SDF-1 binding to CXCR4 in vivo. Our overall
hypothesis was that disruption of SDF-1/CXCR4 signal-
ing would reduce the release of cartilage degenerative
enzymes and attenuate OA pathogenesis.
Materials and methods
Inhibition of the SDF-1/CXCR4 signaling cascade was
evaluated in vitro by using human cartilage explant cul-
tures and human chondrocyte cultures, and in vivo by
using the Duncan Hartley guinea pig model of progres-
sive idiopathic knee osteoarthritis.
Blockage of SDF-1/CXCR4 in human cartilage explants
Cartilage explant culture
The study was approved by the Institutional Review
Board at Rhode Island Hospital, and informed consent
was obtained from each donor. Articular cartilage sam-
ples were obtained from patients with OA at time of
total knee arthroplasty (n = 3); two women (ages 55 and
76 years) and one man (age 55 years). At harvest, the
samples were immediately placed into DMEM culture
medium and transported to the laboratory, where 1.5 ×
0.5-cm square full-thickness cartilage explants were cut
from the normal medial tibia region (Mankin score, 0 to
2) by using scalpels and were placed into 24-well plate
in DMEM culture medium containing 10% FCS (Gibco,
Grand Island, NY, USA) at 37°C in 5% CO2.
The 1.5 × 0.5-cm explants were cut into three equal
parts (0.5 × 0.5 cm) and randomly divided into three treat-
ment groups. Explants in Group 1(n = 3) were incubated
with SDF-1 (250 ng/ml) to evaluate the penetration of
SDF-1 into cartilage. Explants in Group 2 (n = 3) were
incubated in media containing anti-CXCR4 monoclonal
antibody (100 ng/ml; R&D systems Inc., Minneapolis, MN,
USA) plus SDF-1 (250 ng/ml), to evaluate the effect of
receptor blockade. The explants in Group 3 (n = 3) were
left untreated as controls. The cartilage explants and cul-
ture medium were collected on days 2 and 4.
The cultured cartilage explants from each group were
rinsed with HBSS in Tissue-Tek OCT (SakuraFinetek
USA, Torrance, CA, USA) and snap frozen in liquid nitro-
gen. Serial 10-μm sections were cut perpendicular to the
cartilage surface. The sections were fixed for 20 minutes at
-20°C by using 70% ethanol containing 50 mM glycine.
Sections were treated with hyaluronidase (2 mg/ml; Sigma
Chemical Co., St Louis, MO, USA) for 30 minutes at 37°C
(only for SDF-1 and CXCR4 immunostaining) and per-
meabilized in 0.2% Triton X-100/PBS for 5 minutes at
room temperature (RT). Endogenous peroxidase was
quenched, and endogenous biotin and avidin binding sites
were blocked by the sequential incubation with avidin and
biotin for 15 minutes and a blocking solution for 10 min-
utes at RT.
Penetration of SDF-1 into cartilage was evaluated with
immunostaining with anti-SDF-1 antibody (25 μg/ml;
R&D Systems), whereas chemokine receptor CXCR4
was evaluated with anti-CXCR4 antibody (25 μg/ml;
R&D Systems). Both antibodies were applied for 1 hour
at 37°C, followed by incubation with biotinylated sec-
ondary antibodies for 10 minutes at room temperature.
After washing with PBS, sections were incubated with a
streptavidin-peroxidase conjugate for 10 minutes, fol-
lowed by a solution containing diamino-benzidine
(DAB; chromogen) and 0.03% hydrogen peroxide for
5 minutes. Sections were counterstained with hematoxy-
lin. Photographs were taken with a Nikon microscope.
Additional sections were stained with Safranin-O, and
the severity of proteoglycan loss and cartilage damage
was quantified by using the modified Mankin grading
system [16].
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Glycosaminoglycan and MMP-13 release to culture medium
Culture media were collected at the same time as the
cartilage explants (days 2 and 4), and the sulfated-
glycosaminoglycan was quantified spectrophotometri-
cally by using dimethylmethylene blue dye (DMMB)
with bovine chondroitin sulfate as standard controls
[17]. The concentration of MMP-13 activity in the
medium was quantified with ELISA (catalog no.
F13M00; R&D Systems).
Blockage of SDF-1/CXCR4 in cultured human cartilage
cells
Chondrocyte isolation and culture
Chondrocytes were isolated from the OA cartilage samples
described earlier by using our standard method [18]. In
brief, small pieces of cartilage (≈0.5 g) were minced,
digested with pronase (2 mg/ml, Boehringer Roche) for
30 minutes at 37°C, and then digested with bacterial col-
lagenase (1 mg/ml; Type IA, Sigma, C 2674) for 6 to
8 hours at 37°C in a shaker. Residual multicellular aggre-
gates were removed by filtration, and the cells were plated
in DMEM containing 10% FCS, L-glutamine, and antibio-
tics. After cells were grown to confluence, they were split
once (passage 1) and plated either in eight-well chambers
(Nalge Nunc International Corp., Naperville, IL, USA) at
1 × 105 cells/well or in 100-mm-diameter culture dishes
(Becton Dickinson Labware, Franklin Lakes, NJ, USA) at
1 × 106 cells/plate. At 90% confluence, the cells were cul-
tured under serum-free conditions overnight and then
treated with SDF-1 (250 ng/ml) or transfected with SiRNA
CXCR4 for 4 hours before SDF-1 treatment [19].
Blockage of CXCR4 with siRNA
Five micrograms of plasmids containing either the pU6R-
NAi-CXCR4 vector [19] or the pU6RNAi empty vector
[19] (gifts from Dr. Song, University of Washington), were
transfected into these chondrocytes by using a high-effi-
ciency transfection method (Human Chondrocytes
Nucleofector Kit; Amaxa Inc., Gaithersburg, MD, USA).
For 24 hours after transfection, the cells were incubated in
media with or without SDF-1 (250 ng/ml). The total RNA
and cell lysates were collected at 36 and 48 hours, respec-
tively. Real-time RT-PCR was carried out to detect the
expression of CXCR-4 and MMP-13. CXCR4 protein
expression was also evaluated with Western blotting.
Real-time RT-PCR (qPCR)
Total RNA was isolated from chondrocytes with RNeasy
isolation kit (cat. no. 74104; Qiagen USA, Valencia, CA,
USA), as previously described [20]. The 1 μg of total
RNA was transcribed into cDNA by using the iScripTM
cDNA synthesis kit (Bio-Rad, Hercules, CA, USA), and
40 ng/μl of the resulting cDNA was used as the template
to quantify the relative content of mRNA by using Quan-
tiTect SYBR Green PCR kit (Qiagen) with DNA Engine
Opticon 2 Continuous Fluorescence Detection System
(MJ Research, Waltham, MA, USA). The primers were
designed by using Primers Express software (BioTools
Incorporated, Edmonton, AB, Canada), which yielded
CXCR-4 forward (sense) primer, AAA CTG AGA
AGC ATG ACG GAC AA,
CXCR-4 reverse (antisense) primer, GCC AAC ATA
GAC CAC CTT TTC AG,
MMP-13 forward (sense) primer, TGC TGC ATT
CTC CTT CAG GA,
MMP-13 reverse (antisense) primer, ATG CAT CCA
GGG GTC CTG GC,
18S rRNA forward (sense) primer, CGG CTA CCA
CAT CCA AGG AA, and
18S rRNA reverse (antisense) primer, GCT GGA ATT
ACC GCG GCT.
The 18S rRNA was amplified as the internal control.
The cycle threshold values for targets genes were mea-
sured and calculated with computer software (MJ
Research, Waltham, MA, USA). Relative transcript levels
were calculated as × = 2-Δ ΔCt, in which Δ ΔCt = ΔCt E
- ΔCt C, and ΔCt E = Ctexp-Ct18S, and ΔCt C = CtC-
Ct18S.
Western blot
Total protein was extracted from cells and quantified by
using the BAC Protein Assay Kit (Pierce, Rockford. IL,
USA) [21]. In brief, 10 μg of total protein was electrophor-
esed in 10% SDS-PAGE under reducing conditions before
being transferred and probed by a human anti-CXCR4
monoclonal antibody (MAB171, 1:1,000 dilution; R&D
Systems) and anti-b-actin polyclonal antibody (1:1,000
dilution; Cell Signaling Technology, Danvers, MA, USA).
Horseradish peroxidase-conjugated goat anti-mouse or
anti-rabbit immunoglobulin G (IgG) (H+L) (1:3,000 dilu-
tion, Bio-Rad Laboratories, Richmond, CA, USA) was used
as the secondary antibody. Visualization of immunoreac-
tive proteins was achieved by using ECL Western blotting
detection reagents (Amersham, Arlington Heights, IL,
USA) and subsequent exposure of the membrane to
Kodak X-Omat AR film.
AMD3100 blockage of CXCR4 in the Hartley guinea pig
OA model
After receipt of IACUC approval, 35 nine-month-old male
Duncan-Hartley guinea pigs (0.88 kg ± 0.21 kg) were
obtained from Charles River Laboratories (Wilmington,
MA, USA). The animals were allocated randomly into
three experimental groups: Group 1 was left untreated to
serve as a primary OA control (n = 11); Group 2 received
continuous infusion of the CXCR4 blocker AMD3100
(Mozobil; Genzyme) via osmotic minipump (n = 13); and
Group 3 received PBS via constant infusion osmotic mini-
pump (n = 11). All animals were weighed every other
week and euthanized after 3 months (12 weeks) of treat-
ment, at which point, the knees of animals were aspirated,
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and the hindlimbs were removed en bloc via careful
dissection.
Miniosmotic pump implantation and drug delivery
The guinea pigs were anesthetized with a solution of 0.2%
(vol/vol) xylazine (Rompun; Bayer Pharmaceuticals, Brus-
sels, Belgium) and 1% (vol/vol) ketamine (Ketalar; Parke-
Davis, Bornem, Belgium) in PBS. The Mini-osmotic
pumps (model 2006; Alza Corporation, Mountain View,
CA, USA) were inserted into small subcutaneous pockets
over the dorsolateral thorax, created by blunt dissection
after a small incision (~1 cm). Before insertion, the 200-μl
pump reservoirs were filled with 44.44 mg/ml AMD3100
in PBS (Group 2) or PBS alone (Group 3). At an average
pumping rate of 0.15 μl/per hour, each animal in Group
2 received 160 μg AMD3100 per day. Because the pump-
ing duration of the Alzet osmotic pump was 6 weeks, the
pumps were exchanged once during the course of
treatment.
Synovial fluid collection and analysis
At death of the animals, 100 μl of isotonic saline was
injected into both knees of each animal, and the knees
were flexed and extended 10 times before aspiration [22].
This technique typically yielded 160 to 180 μl of saline/
synovial fluid from each animal. The synovial fluid was
centrifuged at 2,000 g for 10 minutes to remove cells and
debris and then was frozen at -80°C until analysis. Five
markers of articular cartilage metabolism were measured
in the synovial fluid samples by following the manufac-
turer’s instructions. SDF-1(catalog no. DSA00), pro-MMP-
1 (catalog no. SMP100), and active MMP-13(catalog no.
F13M00) were measured by using Quantikine ELISA kits
from R&D Systems, whereas IL-1b was measured by using
an IL-1b ELISA kit from Invitrogen (catalog no.
KMC0011C). Colorimetric density of the developed plates
was determined by using a microplate reader set to 450
nm (model BF10000; Packard Bioscience, Meridian, CT,
USA). All ELISA assays were performed in duplicate. Gly-
cosaminoglycan (GAG) concentration was measured by
using a dimethylmethylene blue dye (DMMB) assay [17].
Blood collection and serum analysis
Blood (5 ml) was collected by cardiac puncture immedi-
ately after the animals were killed. The blood was centri-
fuged at 1,800 g for 10 minutes, and the separated serum
samples were then stored at -80°C until analysis. The level
of IL-1b in the serum was measured by using the same IL-
1b ELISA kit and plate-reader settings used for synovial
fluid testing (catalog no. KMC0011C; Invitrogen). As with
the synovial fluid samples, all of the serum samples were
run in duplicate.
Histology
On explantation, gross morphologic lesions on the tibia
plateau were visualized with India-ink staining [23]. The
explanted tibiae were then fixed in 10% formalin for 72
hours, followed by decalcification in 10% EDTA solution.
The tibiae were hemisected on the mid-sagittal plane, and
each half was embedded in a single block of Paraplast
X-tra (Fisher, Santa Clara, CA, USA). Serial 6-μm-thick
sections were cut at intervals of 0 μm, 100 μm, and
200 μm and collected on positively charged glass slides
(Superfrost Plus; Fisher Scientific). The sections were
stained with Safranin-O/fast green. Cartilage degradation
was quantified by using the modified Mankin grading sys-
tem [24]. Three independent and blinded observers scored
each section, and the scores for all of the sections cut
from the medial and lateral tibial plateaus were averaged
within each joint.
Statistical analysis
Analysis of variance (ANOVA) was used in the in vitro
studies to compare the three groups in terms of the con-
centrations of GAG, MMP-13, the relative MMP-13
mRNA levels, and. in the in vivo studies, to evaluate the
concentrations of SDF-1, GAG, pro-MMP-1, active MMP-
13, and IL-1b. The weights of the guinea pigs were
adjusted by using an analysis of covariance (ANCOVA),
and a two-way mixed absolute intraclass correlation coeffi-
cient (ICC) for the modified Mankin score was calculated.
Follow-up pair-wise comparisons between multiple experi-
mental groups were carried out with orthogonal contrasts
by using the Scheffé test (a = 0.05) and a test of homoge-
neity. Adjusted P values for the multiple comparisons
were reported. Differences were considered significant at
P < 0.05. Statistics were performed by using SPSS software
(SPSS Inc.).
Results
SDF-1 penetrated human cartilage explants and
enhanced cartilage matrix degradation
Immunostaining revealed that SDF-1 easily penetrated
human OA cartilage, with > 50% penetration after 1 day of
exposure and complete penetration after 2 days (n = 3)
(Figure 1A). Immunostaining also revealed clear expres-
sion of CXCR4 by OA chondrocytes, which was increased
in osteoarthritic cartilage (n = 3) (Figure 1B). Inspection of
Safranin-O-stained sections revealed matrix degradation
after 2 days of SDF-1 incubation, with significant degen-
erative features after 4 days of incubation, including
decreased pericellular proteoglycan content, enlarged and
empty lacunae, and matrix disruption. (Figure 1C) These
features were attenuated when the explants were incu-
bated with anti-CXCR4 antibody before SDF-1 incubation
(Figure 1C, two right panels). The level of GAG was signif-
icantly higher in media collected from explants treated
with SDF-1 for 4 days, versus explants treated for 2 days,
untreated controls or explants pretreated with anti-
CXCR4 antibody before SDF-1 incubation. (Figure 1D).
Finally, MMP-13 activity was increased twofold in the
medium of cartilage explants treated with SDF-1, but this
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Figure 1 SDF-1 infiltrated cartilage, decreased cartilage proteoglycan content, and increased both glycosaminoglycan and MMP-13
activity levels in the explants culture medium. Immunostaining showed that SDF-1 penetrated cartilage explants partially by day 1 (top
toward bottom) and completely by day 2 of SDF-1 incubation (250 ng/ml) (A). Frozen sections were used to detect CXCR4 expression with
immunohistochemistry. CXCR4 expression was upregulated in osteoarthritic chondrocytes (right panel, B) compared with normal chondrocytes
(left panel, B). Isotype Ig antibody was used as the negative control (middle panel, B). Safranin-O staining of cartilage explants demonstrated
proteoglycan depletion with SDF-1 treatment (C, panels 2 and 3), which was attenuated by pretreatment with anti-CXCR4 antibody (C, panels 4
and 5). Proteoglycan loss in the SDF-1-treated explants began in the pericellular matrix and expanded into the territorial matrix. The absence of
SDF-1 incubation resulted in no loss of proteoglycan (panel 1, C). Spectrophotometry analysis demonstrated increased levels of GAG in the
cultured media of explants treated with SDF-1 and no increase in levels when anti-CXCR4 antibody was preadministered (n = 3). *P < 0.05
compared with no SDF-1 control. ^P < 0.05 compared with SDF-1-treated group (D). ELISA assay showed increased MMP-13 activity in the
cultured media of explants treated with SDF-1 for 2 days, whereas pretreatment with anti-CXCR4 antibody before SDF-1 blocked this increase in
activity (n = 3) (E). *P < 0.05 compared with the control. ^P < 0.05 compared with SDF-1-treated group.
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upregulation was suppressed completely when the SDF-1
pathway was blocked with anti-CXCR-4 antibody (Figure
1E).
siRNA CXCR4 downregulated MMP-13 in human OA
cartilage cells
RT-PCR and Western blot results demonstrated that
siRNA against CXCR4 inhibited both CXCR4 mRNA
transcription and protein expression (Figure 2A).
CXCR4 siRNA also inhibited the expression of MMP-13
(Figure 2B).
AMD3100 attenuated the severity of OA cartilage damage
in vivo
The weight of the AMD3100-treated animals increased
gradually with the time, and at roughly the same rate as
that of the PBS-treated animals and untreated controls,
suggesting that AMD3100 was not overtly toxic (Figure
3A). India-ink staining revealed deep and wide fissures
on the central portion of the medial tibia plateaus in the
animals from the OA and PBS groups, whereas in the
AMD3100-treated group, the cartilage damage was
much less pronounced (Figure 3B). Similarly, H&E and
Safranin-O staining revealed severe OA lesions in the
cartilage from both the PBS-treated group and the pri-
mary OA controls, with only minor OA changes
observed in the AMD3100-treated group (Figure 3C and
3D). The Modified Mankin scores in both the primary
OA and PBS control groups reflected severe degenera-
tion (12.08 ± 2.56 and 10.18 ± 3.77, respectively; P =
0.308) (Figure 3E), whereas cartilage damage in the
AMD3100-treated group was significantly less (6.45 ±
1.83; P < 0.01 for both). In the AMD 3100-treated ani-
mals, the GAG level in synovial fluid was 0.51 ± 0.09
μg/ml, which was significantly lower than that in the
primary OA (0.66 ± 0.05 μg/ml; P = 0.006), and the
PBS-treated groups (0.62 ± 0.10 μg/ml; P = 0.045) (Fig-
ure 3F).
AMD3100 reduced the level of SDF-1, MMPs, and IL-1b in
synovial fluid and of IL-1b in serum
AMD3100 reduced the levels of SDF-1, pro-MMP-1,
active MMP-13, and IL-1b in the synovial fluid by 39%,
45%, 13%, and 45%, respectively, and reduced the serum
IL-1b by 48%, in comparison to the untreated OA con-
trols (Table 1). As expected, the synovial fluid levels of
SDF-1, pro-MMP-1, active MMP-13, and IL-1b, and the
level of IL-1b in serum were very similar in the PBS-
treated animals and the untreated OA controls.
Discussion
Osteoarthritis (OA) is a common and disabling disease,
but the mechanisms that drive the disease are unclear.
Although the etiology is likely multifactorial, increasing
evidence has suggested that the synovium is involved in
the induction of cartilage degradation during OA and
RA development [10,15]. The results of this and other
studies [10,14,15,18,22] suggest that the chemokine
SDF-1 plays an important role in the development of
OA. A complementary expression pattern exists between
SDF-1 and CXCR4; the synovium produces SDF-1,
whereas its receptor, CXCR4 is preferentially expressed
by articular chondrocytes [7]. Kanbe et al. [10] showed
that human chondrocytes expressed functional chemo-
kine receptors and released MMP-3 and MMP-13 in
response to SDF-1 [10,15,25]. In organ culture, we
showed that high concentrations of SDF-1 (250 ng/ml),
comparable to levels observed in the synovial fluid of
osteoarthritic knees (> 200 ng/ml), can readily penetrate
the articular cartilage. This suggests that SDF-1 synthe-
sized by synovial cells can diffuse freely into the adja-
cent cartilage. Previous studies showed that SDF-1 binds
to glycosaminoglycans in the extracellular matrix or on
the cell surface [26-28], which may stabilize SDF-1 and
result in its accumulation around chondrocytes. Pericel-
lular accumulation of SDF-1 around OA chondrocytes,
in which CXCR4 is upregulated [15] (Figure 1B), could
heighten the response to SDF-1 and induce cartilage
matrix degradation.
With Safranin-O staining, we demonstrated that the
cartilage explants treated with SDF-1 for as little as 2
days had significantly less proteoglycan (PG) content
than did untreated explants, whereas GAG levels were
higher in the media of explants treated with SDF-1.
This result is consistent with the findings of previous
studies in which severe OA is associated with a decrease
in PG content [29,30]. Enlarged and empty lacunae were
also observed in the cartilage treated with SDF-1, con-
sistent with previous studies linking OA to decreased
chondrocyte numbers and empty lacunae [31-33].
In our investigation, the cartilage-degrading enzyme
MMP-13 was upregulated with SDF-1 treatment. This is
consistent with previous studies, which showed that
SDF-1 increases MMP-3 and MMP-13 levels in a dose-
dependent manner [9,14,15,34]. We also demonstrated
that the SDF-1-induced increases of MMP-13 levels can
be disrupted by blocking the SDF-1 pathway with either
anti-CXCR4 antibodies or siRNA directed against the
CXCR4. Based on these findings, we propose that in
OA, the synovium produces high levels of SDF-1 which
induces matrix degradation via the release of MMP-13.
Loss of the matrix disrupts the microenvironment sur-
rounding chondrocytes, which leads to cell dysfunction
and death. The cycle between matrix degradation and
chondrocyte loss ultimately results in gross changes in
cartilage characteristics of OA.
To test whether disruption of SDF-1 signaling could
attenuate OA pathogenesis in vivo, we treated the
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primary Hartley guinea pig OA model with AMD3100, a
specific nonpeptide CXCR4 chemokine receptor antago-
nist [35]. Dunkin Hartley guinea pigs develop sponta-
neous OA of the knee at around age 9 months, and the
gross lesions are invariably present at 12 months
[30,36]. The data of body weight indicated the animal
tolerated AMD3100 well at the dose of 160 μg/per day,
a dose that has been reported safe in animals and
humans [37-39]. After 3 months of treatment, the gross
and histology observations displayed less cartilage
damage compared with the primary OA group and the
sham group. The cartilage damage severity quantified by
Figure 2 Knockdown CXCR4 by SiRNA CXCR4 decreased MMP-13 mRNA level. Chondrocytes were transfected with the pU6RNAi-CXCR4
siRNA or a control vector and then treated with SDF-1. Total RNA and protein were isolated for RT-PCR and Western blot, respectively.
Transfection with siRNA against CXCR4 inhibited both CXCR4 mRNA and protein in comparison with the control samples without SiRNA CXCR4.
(A) MMP-13 mRNA levels increased when SDF-1 was administered. Treatment with SiRNA CXCR4 before SDF-1 incubation eliminated the
increase in MMP-13 mRNA. (B) Bar graphs show the averages of quantified data of MMP-13 mRNA from three independent experiments (n = 3).
*P < 0.05 compared with control.
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Figure 3 Blocking SDF-1/CXCR4 signaling by AMD3100 attenuated the severity of OA cartilage in Hartley primary OA guinea pig
model. The weight of the animals increased gradually with time, with no significant difference among the AMD3100-treated group, 12-month
primary OA group, and the sham group at any time (A). India-ink stain revealed typical OA lesions in the primary OA group and PBS-treated
group, whereas less staining and fewer fissures were noticed in the AMD3100-treated group (B). H&E and Safranin-O staining showed less
cartilage damage for the AMD3100-treated knees as compared with the 12-month primary OA and sham joints. Loss of proteoglycan staining
and cartilage destruction was evident in the 12-month primary OA and sham joints (C, D). Guinea pig Mankin score shows no significant
difference between the primary OA group and the PBS-treated group on cartilage damage, whereas the cartilage damage in these two groups
was much greater than that of the AMD3100-treated group (E). The high concentration of GAG in primary OA and PBS-treated groups was
attenuated in the animals treated with AMD3100 (F). Data are expressed as mean ± SD. AMD3100 group, n = 13; primary OA group, n = 11; PBS
group, n = 11. *P < 0.05.
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the Mankin score further indicates that AMD3100 treat-
ment has the lowest Mankin score, almost half that of
the primary OA group. Thus, the OA severity was atte-
nuated by the injection of AMD3100.
Elevated concentrations of SDF-1 in synovial fluid
have been observed in OA patients [10] and the guinea
pig OA model [22]. Our data demonstrate that this
pathologic elevation can be inhibited by blocking SDF-
1/CXCR4 signaling with AMD3100. The regulation of
SDF-1 expression is not fully understood. One study
found that hypoxic conditions in the synovium of rheu-
matoid arthritis may induce production of SDF-1, con-
tributing to the persistence of synovitis [40]. Other
recent studies showed that interleukin-1 appears to
induce SDF-1 expression in human subacromial bursa
[41], and that SDF-1 expression in bursal cells can be
inhibited by steroid and nonsteroidal antiinflammatory
agents [42]. These studies suggest that SDF-1 levels are
likely associated with the progression of inflammation.
In this study, blockage of the SDF-1/CXCR4 pathway by
AMD3100 reduced the level of IL-1, which indirectly
reduced SDF-1 level in synovial fluid through the IL-1-
SDF-1 regulation pathway.
AMD3100 also reduced the level of GAG, MMP-13,
MMP-1, and IL-1b in synovial fluid and IL-1b in serum.
Matrix metalloproteinases (MMPs) play an important
role in the extracellular matrix degradation [43]. Pre-
vious work showed that MMPs are regulated by the
SDF-1/CXCR4 axis in OA and growth-plate chondro-
cytes [10,14,18]. In the present study, AMD3100 inhib-
ited MMP-1 and MMP-13 release in OA animals. Thus
this association raises the intriguing possibility that
AMD3100 may reduce MMPs expression through the
SDF-1/CXCR4 axis. IL-1b is one of the important fac-
tors in OA pathogenesis [44] causing collagen and
aggrecan breakdown [45]. Targeted reduction of IL-1b
via RNAi in guinea pig chondrocytes showed beneficial
effect on the OA pathogenesis [46]. In our study, the
IL-1b level in synovial fluid is much higher than in
serum, which is consistent with previous reports
[47-49]. Our study shows that AMD3100 decreases the
IL-1b levels in both synovial fluid and serum, which
may reduce its harmful effects on OA progression.
Our research suggests that chemokines, along with
proinflammatory cytokines, play critical roles in the
pathogenesis of OA. We demonstrated that SDF-1/
CXCR4 signaling directly induces cartilage matrix degra-
dation via MMP-13 release, and that this destruction
can be inhibited by blocking the SDF-1/CXCR4 path-
way. The loss of matrix integrity directly compromises
the mechanical properties of cartilage and may act as an
accelerating force in the progression of OA. We also
demonstrated that AMD3100 decreases the level of sev-
eral OA-related factors in our animal model, attenuating
the severity of primary OA. The age-related tissue wear
results in fibrillation of the articular surface. This
mechanical damage of the cartilage surface allows
increasing amounts of inflammatory chemokines, such
as SDF-1, to infiltrate into the cartilage. Once in the
matrix, SDF-1 can then interact with CXCR4 on the cell
surface, resulting in the release of MMPs and subse-
quent cartilage degeneration. Addition of AMD3100
blocked the binding of SDF-1 with CXCR4, removing
the stimulatory trigger for the release of matrix-degrad-
ing enzymes, such as MMPs. Thus, further damage of
the joint was suppressed.
Conclusions
In summary, in this study, we demonstrated that SDF-1
directly induces cartilage matrix degradation via MMP-
13 release and that the severity of OA cartilage degen-
eration can be attenuated by blocking SDF-1/CXCR4
signaling. Our data present a novel therapeutic target
for the prevention and treatment of osteoarthritis.
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